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Schistosomiasis remains a public health
problem in many regions, including Africa, the
Middle East, Asia, and South America (1). For
many of the Schistosoma species that infect
humans, isoquinolin-4-one, praziquantel, is the
only effective drug (2,3). Its minimal side effects
and high degree of efficacy against both
trematodes and cestodes have made it the drug of
choice for many human and veterinary parasitic
infections (2,4). However, praziquantel has been
in use for more than 20 years (5), and concern is
increasing that resistance has emerged, or will
soon emerge, in human parasites (6,7).
Loss of praziquantel efficacy would set back
helminth control efforts. Many community-based
programs depend on praziquantel for treating
patients with schistosomiasis, cysticercosis,
echinococcosis, and tapeworm and other fluke
infections (5,8-13). Concern over possible loss of
efficacy prompted the European Commission
to establish an International Initiative on
Praziquantel Use, which met in February 1998
(14) and again in February 1999 (15). The group
reviewed reports of low efficacy in clinical trials
in Senegal and Egypt (16-19) and of laboratory
isolation of schistosome strains resistant to
standard and high doses of the drug (20-23).
Although there was no definitive laboratory
evidence of genetically transmissible and drug-
selectable resistance (as had been demonstrated
for the antischistosome drug hycanthone [24]),
concern was raised over possible low-level
resistance. The need was expressed for continued
monitoring for resistant strains under the
pressure of widespread praziquantel use (14).
We examined drug efficacy in the community
and among schoolchildren given repeated
praziquantel treatment for S. haematobium in
Coast Province, Kenya. Year-to-year variation in
treatment response was assessed, and the likely
time-to-emergence of resistance was evaluated
through the use of mathematical modeling of




The overall goal of the community study was
to treat urinary schistosomiasis in schoolchildren
(initial N = 3,196) in a nine-village area in Kwale
District, Coast Province, Kenya. After oral
informed consent was obtained under a human
investigations protocol approved by the institu-
tional review boards of University Hospitals of
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case-finding was performed by school-based and
follow-up village surveys. Details of the protocols
have been published (25-27). In 1984, the initial
treatment year, S. haematobium-infected chil-
dren were randomly assigned to groups for
treatment with either praziquantel (Biltricide,
Bayer, Leverkusen, Germany), 40 mg/kg once a
year, or metrifonate (Bilarcil, Bayer), 10 mg/kg
three times a year. In years 2 and 3, the initial
treatment was repeated, independent of parasi-
tologic findings. New entrants to the study were
assigned randomly to either the praziquantel or
metrifonate treatment groups, according to the
original 1984 protocol. In 1987, half the 1984
cohort, treated either with praziquantel or with
metrifonate, was randomized to receive a single
dose of metrifonate, 10 mg/kg, as a “consolida-
tion” treatment. After a 2-year hiatus, annual
treatment was resumed in 1989 to 1991; during
this period, only children in whose urine samples
eggs were identified (egg-positive children) were
treated with praziquantel alone.
Infection status was determined by Nuclepore
(Whatman, Kent, UK) filtration of two 10-mL
samples from stirred midday urine specimens.
Infection-associated disease was determined by
physical examination, dipstick urine examina-
tion for hematuria and proteinuria, and
ultrasound examination of the kidneys and
bladder (25). Clinical and parasitologic testing
was performed each year. Results were coded and
entered for analysis in databases at Case
Western Reserve University and the Kenyan
Ministry of Health.
Data Analysis
Results of annual treatments were scored as
“cure” for patients whose status changed from
egg-positive to egg-negative, “noncure” for those
whose status remained egg-positive, and “in-
fected or reinfected” for those whose status
changed from egg-negative to egg-positive
between yearly examinations. Because of the
skewed distribution of egg counts in the infected
population, the effects of treatment on average
intensity of infection were assessed by
determining the change in geometric mean egg
count between examinations. Differences be-
tween outcome rates were assessed by the chi-
square test with Yates’ correction or Fisher’s
exact test.
Mathematical Modeling
The potential for development of praziquantel
resistance in the study population was first
estimated by the Hardy-Weinberg equilibrium
analysis (28). We then used a deterministic,
simultaneous differential equation model of
helminth resistance (Appendix, 29). This more
advanced model takes into account the skewed
(negative binomial) distribution of number of
worms in human populations, the obligate sexual
reproduction of the parasites, and a possible
decrease in fecundity as a result of parasite
crowding in heavily infected humans. The model
provides estimates of average level of infection in
the study population, as well as the prevalence
and density of resistant worms over time. Results
are shown as three-dimensional graphs of mean
numbers of worms over time (20 years), as a
function of annual community drug use (p), and
the reproductive fitness of resistant parasites.
Treatment efficacy and aggregation constants for
infection (k) were derived from our study area.
Results
Yearly Efficacy of Praziquantel
During 1984 to 1992, we observed substantial
year-to-year variations in cure rates (conversion
from egg-positive to egg-negative status on urine
Nuclepore filtration examination) for both
praziquantel and metrifonate (Table 1). The
response to metrifonate treatment declined each
year, from 79% in 1984 to 47% in 1987 (p <0.001,
Figure 1); in contrast, we observed no consistent
downward trend in response to praziquantel
treatment, despite repeated use of the drug in
many patients (Figures 1 and 2). However, the
response to praziquantel varied significantly
from year to year (p <0.001), from a cure rate of
96% in 1990 (year 7 of the project) to a cure rate of
65% in 1986 (year 3, p <0.001). This level of
efficacy was within the previous range of
S. haematobium cure rates, both in Coast
Province and elsewhere in Africa (Table 2). In
suppression of infection intensity, the
praziquantel-mediated reduction of mean S.
haematobium egg counts was consistently >83%
for all years of observation.
Impact of Repeated Treatment
In both the study periods during which
repeated, annual praziquantel treatment was587
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Table 1. Effectiveness of praziquantel in eliminating Schistosoma haematobium infection, Msambweni, Coast Province,
Kenya, 1984-1992
Prevalence of infection at 12 months after treatment
Patient’s (interval change in geometric mean of (egg count + 1) for group)
infection and Year treated with PZQ or metrifonate
treatment status 1984 1985 1986 1987 1989 1990 1991
Egg-positive urine,     17%     12%     34%       -    15%       4%     35%
Given PZQ, never (97 to 1.5) (33 to 1.5) (29 to 3.7) (18 to 1.5) (22 to 1.1)  (24 to 4)
previously treated   n = 981    n = 51    n = 82   n = 352    n = 292  n = 274
Egg-positive urine,        -     13%     38%       -      10%       2%     29%
Given PZQ, had  >1 (10 to 1.5) (16 to 2.6) (19 to 1.1) (14 to 1.0) (13 to 2.8)
PZQ treatments    n = 111    n = 47    n = 68    n = 73   n = 64
All egg-positive,     17%     13%     35%       -      14%       4%     34%
PZQ-treated patients (97 to 1.5) (15 to 1.5) (24 to 3.3) (19 to 1.4) (20 to 1.1) (22 to 3.8)
  n = 981    n = 162   n = 129   n = 420   n = 365   n = 338
Infection rate     15%       9%     11%     11%      13%     10%     21%
(egg - to egg + conversion)
All patients, treated and     18%     12%     14%     19%      14%     13%     24%
untreated n = 3,196  n =2,498 n = 2,372 n = 1,968 n = 1,398 n = 2,579 n = 1,938
PZQ = praziquantel.
Figure 1. Yearly efficacy of drug therapy. Results of
praziquantel treatment (solid bars) or metrifonate
treatment (shaded bars) for Schistosoma haematobium
infection in the Msambweni area during 1984 to 1992.
Cure rates (conversion from egg-positive to egg-
negative urine in annual follow-up testing) are shown
for all egg-positive cases, by year of treatment. Only
metrifonate therapy was given in 1987, and no
treatment was given in 1988.
Figure 2. Efficacy of praziquantel therapy for
Schistosoma haematobium according to prior treat-
ment status. Solid bars indicate yearly cure rates for
patients receiving their first praziquantel treatment.
Hatched bars indicate cure rates for children with a
history of prior praziquantel treatment. No significant
differences in efficacy were noted in any of the years
studied (1985-1991).
used (1984-1987 and 1989-1993), the observed
cure rate for egg-positive children increased in
year 2 of treatment, then decreased in year 3
(Figure 1). The number of egg-positive children
remaining to be treated in successive years was
small, and this sample did not have sufficient
statistical power to determine whether the year 3
decrease in praziquantel response was due to
fluctuations in transmission (30), progressive
selection of patients at high risk for exposure to
S. haematobium (27,31), or gradual selection of
praziquantel-resistant parasites.588
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Given the incomplete efficacy of praziquantel
in eradicating infection (6) and the single annual
follow-up, our study design could not distinguish
reinfection from possible drug failure. Therefore,
we used several indirect variables to estimate
ongoing praziquantel efficacy: the level of
persistent egg-positivity at 1 year after
praziquantel treatment, compared with rates of
new infection (egg-negative to egg-positive
conversion) each year; the efficacy of the drug in
children receiving a second, third, or fourth dose,
compared with efficacy in children receiving a
first dose; and the efficacy of the drug in children
who remained egg-positive after their first dose
compared with efficacy in children whose infections
cleared but who subsequently became reinfected.
Persistent Infection vs. Reinfection
The yearly efficacy of praziquantel treatment
and infection or reinfection rates (egg-negative to
egg-positive conversion) were compiled for the
study population (Table 1). Yearly infection or
reinfection rates varied from 15% in 1984 to 1985
to a low of 9% in 1985 to 1986 and a high of 21% in
1991 to 1992 (average 13%). Infection rates for
children initially treated with praziquantel who
subsequently missed 1 year or more of treatment
were 22% to 34% in subsequent surveys 2 to 4
years later. These rates suggested a time-
dependent average accumulation of reinfection at
an annual rate of 9% to 15%. The high
transmission levels in 1991 to 1992 (21% new
infection or reinfection) may explain the
apparent decrease in praziquantel efficacy
during this 12-month period. However, esti-
mated transmission did not explain the decreased
efficacy seen in 1986 to 1987, when the
population egg-negative to -positive conversion
rate was only 11%.
Efficacy of Retreatment with Praziquantel
To examine whether an increasing core of
resistant infection might account for the higher
post-treatment prevalence after year 2 of
treatment, we compared the relative annual
efficacy in egg-positive patients who received
praziquantel for the first time with efficacy in
patients receiving their second, third, or fourth
treatments. We found that after the first cycle of
treatment, i.e., from 1985 on, praziquantel-
mediated cure rates did not differ for patients
with first-time treatment and those with a
history of praziquantel treatment (Figure 2). We
further examined the response to second, third,
and fourth treatments in patients who did not
become egg-negative after their first dose (i.e.,
initial nonresponse, possibly resistant) (Figure 3).
We compared these results with those of patients
who tested negative after the first praziquantel
dose, then became egg-positive in later years
(those reinfected after cure, Figure 3). Children
from these two groups, who were at greatest risk
for infection with resistant parasites, eventually
reverted to egg-negative status after treatment
with one to three supplemental praziquantel
doses. The two groups did not differ significantly in
their response rates to the second, third, or fourth
doses.
Discussion
Without clear evidence of emerging resis-
tance in our treated population, we considered
Table 2. Reported praziquantel (40 mg/kg) efficacy for Schistosoma haematobium, Coast Province, Kenya, and
elsewhere in Africa
Cure rate(s)
Site observed (%)  Year(s)              Reference
Coast Province, Kenya
Kajiwe, Kilifi district 62-65 1994 Olds et al., 45
Msambweni area, Kwale district 65-96 1984-91 present study
Southern Kwale district 84 1986 King et al., 46
Kwale district 87 1986 Stephenson et al., 47
Elsewhere
Senegal 80-93 1995 Shaw et al., 48
Ghana 67 1994 Chan et al., 9
Zimbabwe 72 1986 Taylor et al, 49
Mauritania 90-95 1985-86 Etard et al., 50
Ghana 60 1984 Mott et al., 42
Egypt 59-62 1983 el Malatawy et al., 51
Gambia 57-93 1983 Wilkins et al., 52
Tanzania 66-83 1979 McMahon and Kolstrup, 53589
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Figure 4. a. Hardy-Weinberg equilibrium analysis of
the increase in resistance gene frequency in a parasite
population where the initial R gene frequency is 10-6,
heterozygotes and R gene homozygotes are fully
resistant, and 75% of susceptible worms are lost to
treatment each generation.  b. As in a, but 40% of
heterozygotes are lost to treatment each generation.  c.
As in a, but 99% of resistant homozygotes do not
survive to reproduce.
Figure 3. Extra doses needed to cure Schistosoma
haematobium infection in 1984-entry cohort children
who were not cured with a first dose of praziquantel
(initial nonresponse, N=123, top bar) compared with
doses needed to cure children reinfected after successful
praziquantel treatment (reinfected post-cure, N= 36,
bottom bar). The filled areas in each bar indicate
percentage of each group requiring one (solid), two
(hatched), or three (shaded) more doses of praziquantel to
become egg negative. No significant differences were
observed between the two groups in age, sex, or cure
rates.
two related questions: Why was resistance not
observed, and when might it be expected to
emerge under the field conditions tested? To
answer these questions, we turned to mathemati-
cal models of inheritance of drug resistance.
A number of factors may account for the lack
of evidence of praziquantel resistance in the
Msambweni project. Although S. haematobium
resistance to praziquantel is likely to emerge at
some future time, the interval required for
detection of resistance may be much longer than
our 8-year observation period. An effective
praziquantel-resistance mutation may be so rare
that the number of generations required for it to
become the dominant phenotype has not yet
occurred. In Egypt, for example, apparently
resistant strains of S. mansoni are emerging >10
years after widespread availability of praziquantel
treatment (32). For a single resistance gene
mutation beginning at frequency of 10-6, a Hardy-
Weinberg equilibrium analysis (28) predicts it
would take eight or more generations for the
resistant phenotype to become clinically detect-
able (i.e., 25% to 50% of worms) at the community
treatment rates used in this study, if the
resistance gene heterozygotes are fully resistant
to treatment (i.e., a dominant trait [Figure 4a]).
In our study, we estimate that 25% to 50% of
infections were treated, but because the targeted590
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school-age groups have the highest numbers of
worms, 50% to 75% of worms may have been
exposed to praziquantel. Emergence times for the
resistance phenotype are longer if heterozygotes
remain fully or partially susceptible to the drug
(11 generations for 25% heterozygote loss after
treatment and 14 to 18 generations for 50%
heterozygote losses) and only the homozygotes
are fully resistant (Figure 4b). Given the seasonal
nature of rainfall and water exposure, the
requirement of two sexes for schistosome
reproduction, and the uneven aggregation of
worms in the human population, the effective
generation time for S. haematobium is likely to be
at least 6 to 12 months, so we observed no more
than 8 to 16 generations; our observation period
may have been too short to identify praziquantel
resistance. Our annual follow-up was an
insensitive means to detect drug failure due to
resistance. However, under the pressure of
continued praziquantel treatment in the commu-
nity, if resistant worms are fully fit, rapid
predominance of resistant strains would be
expected (Figure 4).
Praziquantel failure on initial treatment in
S. mansoni-endemic areas of Senegal suggests
primary resistance to praziquantel (16,18) and a
high prevalence of resistance genes in the local
S. mansoni strain (21,33,34). More recent reports
indicate, however, that in this area of Senegal,
retreatment after 40 days adequately reduces
infection levels and achieves better cure rates
(19). The latter results suggest that immature
schistosomes, which are known not to be
susceptible to praziquantel, are typically present
in Senegalese patients at the time of treatment. If
the treated patient has been recently exposed to
infection (<6 weeks ago) in an area with
continuous—rather than seasonal—transmis-
sion, apparent treatment failure may be observed
when unaffected juvenile worms reach maturity
and pass eggs several weeks after praziquantel
treatment (14). Annual reinfection rates for
S. haematobium may be high in some areas, such
as Niger (35), and post-treatment infection
detected after a single round of therapy should
not be immediately interpreted as evidence of
praziquantel resistance.
Nevertheless, animal studies of S. mansoni
strains from Senegal indicate they are less
sensitive to praziquantel than strains from other
parts of the world (21,33,34). There is another
explanation for an apparent low-level prevalence
of drug resistance that fails to predominate in the
parasite population: if a praziquantel-resistance
mutation compromises reproductive fitness, the
homozygous, fully resistant worm will never
predominate. Instead, under the pressure of
continued treatment, the resistance gene will
achieve a stable-equilibrium share of the worm
population, at a level dependent on its lower
survival efficiency relative to that of the
praziquantel-sensitive genotype (Figure 4c). This
situation is analogous to the effect of the sickle
cell-hemoglobin gene in human populations
exposed to malaria.
Another possible factor likely to be slowing
the emergence of praziquantel resistance in
Schistosoma is the parasite’s obligate diecious
sexual reproduction. Unlike drug-resistant bac-
teria, praziquantel-resistant schistosomes must
find a mate of the opposite sex to reproduce,
which requires a sufficient density of human
infection. In a disease-endemic area where most
of the population has been treated, the initial
heavy loss of susceptible worms (>80%) may
actually reduce mean number of worms
sufficiently (i.e., to fewer than one male and one
female per host) to prevent most resistant worms
from finding suitable mates (29). Worm
distribution is highly aggregated in the human
population, with most (75%) patients having light
infections and a small proportion (approximately
5%) having heavy infections. Heavy infection can
result in reduced worm fecundity, slowing the
production of eggs and thus the transmission of
genes from a resistant worm, even though the
chances of mating are enhanced. After treatment,
the reduced number of worms in a heavily
infected human could increase fecundity, so the
net effect of treatment on praziquantel-
resistance gene transmission would be difficult to
predict. In an age-targeted program such as ours,
praziquantel-sensitive parasites would also
persist in the untreated adult and infant human
subpopulations, slowing the dominance of drug
resistance gene(s). This would occur by allowing
interbreeding of resistant and susceptible worms
in host locations not having the environmental
pressure (i.e., praziquantel treatment) that
favors the resistance gene.
Using a dynamic model of parasite transmis-
sion that accounts for these reproductive features
of macroparasite transmission (Appendix), we
examined the impact of treatment coverage and
duration of control programs on the emergence of591
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resistant infection, to estimate the time required
for drug failure. We also examined the impact of
varying reproductive fitness of the resistant
worms on the time to recrudescence of infection.
Figures 5 and 6 show the predicted recrudescence
of infection over a 20-year period, as influenced
by treatment coverage and by reproductive
fitness of resistant worms. Both simulations
indicate at least an 8- to 10-year delay in the
return of infection to pretreatment levels. This
delay is especially noted if treatment coverage is
incomplete (Figure 5) and resistant parasites are
less reproductively fit than susceptible ones
(Figure 6). The model further indicates that
under the conditions of our program (targeted
mass treatment, with 25% to 75% of infections
praziquantel-treated), resistance becomes clini-
cally apparent (>50% resistant worms) only after
a period years longer than that we were able to
observe.
In our model, we assumed an effective
spontaneous mutation rate for praziquantel
resistance of 10-6. Recent work by Moxon and
colleagues (36-38) on the evolution of bacterial
pathogens indicates that genetic mutation
becomes accelerated (i.e., nonrandom) in a subset
of organisms under environmental stress, such
as drug pressure. The “hypermutable” phenotype
prevails under these rapidly changing conditions
because of its ability to adapt quickly to the new
environment. Rapid genetic diversification is
enhanced by simultaneous modular changes in
DNA, which are facilitated by the presence of
multiple copies of critical genes, transposons, and
repeat regions or Z-DNA boundaries flanking key
intron/exon boundaries (39). Higher organisms,
such as schistosomes, are likely to use similar
mechanisms in adaptation. Drake (40) has
estimated that the effective spontaneous muta-
tion rate per genome per sexual generation may
be as high as 10-2 for the nematode C. elegans and
10-1 for the insect Drosophila. In sensitivity
analysis of our differential model, reducing the
mutation rate from 10-6 to 10-1 in our base case
(50% coverage with 85% efficacy) reduced the
expected time to emergence of resistance from 10
to 7 years. At higher levels of drug use (90%-100%
coverage), the time to resistance was reduced
from 7 to 5 years at the highest mutation rate
(10-1). This effect is not as dramatic as would be
predicted by the simpler Hardy-Weinberg model
Figure 5. Three-dimensional graph of estimated mean
community level of infection over time (20 years) as a
function of the proportion of infections treated each
year (20% to 100%). Results are obtained from the
model described in the appendix. Resurgence of
infection (due to emergence of resistance) was
predicted to occur soonest (~7 years) when yearly
treatment coverage was greatest (100%). Under the
conditions of our study (25% to 75% coverage),
detectable increases in community level of infection
(due to resistance) were estimated to take a minimum
of 10 to 15 years.
Figure 6. Three-dimensional graph of mean commu-
nity level of infection, over time, as a function of the
reproductive fitness of resistant parasites during an
ongoing control program in which 50% of infected
patients are treated each year. Limited fitness of
resistant parasites (<0.6) delays or severely limits the
reemergence of parasite infection intensity.592
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(i.e., a reduction from 14 to 3 generations for
dominance of resistance), apparently because of
the retarding effects of aggregation and mating
on emergence of new genotypes.
In summary, our results indicate that
significant resistance to praziquantel treatment
had not emerged in S. haematobium in the
Msambweni area as of 1991. As noted since its
first use, praziquantel treatment was not 100%
effective in eliminating infection (41). It was,
however, reliably capable of suppressing inten-
sity of infection in each of six rounds of treatment
spaced over 8 years. These findings, together
with our modeling analysis, support targeted use
of chemotherapy for disease control in
S. haematobium-endemic populations (1,26,42-
44). In our program, praziquantel treatment was
focused only on schoolchildren, the subpopula-
tion having the highest numbers of worms
(26,27).  Higher treatment coverage increases
evolutionary pressure on the schistosome
population and hastens emergence of resistance.
The limited coverage of a targeted (vs. mass-
treatment) program may have reduced the
tendency for resistance to emerge, compared
with the experience reported for S. mansoni in
Egypt (32).
For the treated Msambweni population, the
benefits of treatment appeared to be maximal
after 2 years of repeated yearly treatment
(26,27). After this, a 2- to 3-year interval may be
sufficient to maintain effective suppression of
infection and disease (27). Because reduced
exposure to the drug slows the emergence of drug
resistance, the efficacy of longer intertreatment
intervals in suppressing S. haematobium-related
disease should be studied. Although efficacy
should be maintained for a number of years,
regular monitoring of drug efficacy is appropriate
for all long-term praziquantel-based control
programs (14). Emergence of praziquantel
resistance should be anticipated within 10 to 20
years, and continued antischistosomal drug
development should be pursued.
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Appendix
The following system of differential equations was used to model the level of schistosome infection and prevalence of
resistant worms in the treated study population, where
σ  is the number of sensitive schistosomes per host,
ρ  is the number of resistant schistosomes per host, and
σ + ρ  = M, the mean number of worms per host.
If p = the proportion of treated infections each year, and
h = the efficacy of one course of treatment, then
c = - ln (1- ph) is the relative increase in the per capita death rate of sensitive worms due to treatment.
The basic death rate for sensitive and resistant parasites is an aggregate function of parasite and host death rates,
represented in the equations as
γγγγγ s =
                        1          1
sensitive parasite lifespan  +  host lifespan
and
γγγγγ r =
                        1          1
resistant parasite lifespan  +  host lifespan
R0 represents the basic reproductive rate of the susceptible worm. If  φ  = the relative loss of reproductive fitness of the
resistant phenotype (with value from 0 to 1), then R0r = R0 (1 - φ ).  Χ  represents the spontaneous mutation rate of resistant
worms. To reflect the impact of obligate sexual mating and unequal distribution of worms among hosts, F is a fecundity
expression where
Ψ  = the mating probability,
 z  = the density-dependent effect on worm fecundity, and
 k  = the aggregation constant of the negative binomial distribution of worms,
such that
Then, along the lines of equation 17.5 of Anderson and May (29) for repeated treatment,
and assuming resistant parasites to be completely unaffected by treatment,
For the numerical analysis of these equations, we used the ODE solver of MathCAD (MathSoft, Inc., Cambridge MA) based on
the Runge-Kutta estimation with  1,000 steps for a model time span of 20 years.
Initial variable estimates were taken from our field data (treatment coverage among total infected population, p = 0.25 to
0.75; treatment efficacy, h = .65 to .95; aggregation constant, k = 0.067; host lifespan = 50 years) or from previously published
estimates for S. haematobium biology (R0 = 2 to 4; parasite lifespan = 3 to 5 years; density effect on fecundity, z = 0.96 to 0.99)
(29).
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